Evidence map›Paper›PMID 29025634›Full record

ArticleThe Lancet. Global health2017

Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study.

Stéphane Verguet, Carlos Riumallo-Herl, Gabriela B Gomez, Nicolas A Menzies, Rein M G J Houben, Tom Sumner, Marek Lalli, Richard G White, Joshua A Salomon, Ted Cohen and 7 more

Open access · goldAbstract read
In one paragraph

Article in The Lancet. Global health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
10.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 7 countries.

Stéphane VerguetDepartment of Global Health and Population, Harvard T H Chan School of Public Health, Boston, MA, USA. Electronic address: verguet@hsph.harvard.edu.
Carlos Riumallo-HerlDepartment of Global Health and Population, Harvard T H Chan School of Public Health, Boston, MA, USA.
Gabriela B GomezDepartment of Global Health, Amsterdam Institute for Global Health and Development, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands; Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.
Nicolas A MenziesDepartment of Global Health and Population, Harvard T H Chan School of Public Health, Boston, MA, USA.
Rein M G J HoubenTB Modelling Group, TB Centre, London School of Hygiene and Tropical Medicine, London, UK; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Tom SumnerTB Modelling Group, TB Centre, London School of Hygiene and Tropical Medicine, London, UK; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Marek LalliTB Modelling Group, TB Centre, London School of Hygiene and Tropical Medicine, London, UK; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Richard G WhiteTB Modelling Group, TB Centre, London School of Hygiene and Tropical Medicine, London, UK; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Joshua A SalomonDepartment of Global Health and Population, Harvard T H Chan School of Public Health, Boston, MA, USA.
Ted CohenDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Nicola FosterHealth Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Susmita ChatterjeePublic Health Foundation of India, New Delhi, India.
Sedona SweeneyDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.
Inés Garcia BaenaGlobal TB Programme, WHO, Geneva, Switzerland.
Knut LönnrothGlobal TB Programme, WHO, Geneva, Switzerland; Department of Public Health Science, Karolinska Institutet, Stockholm, Sweden.
Diana E WeilGlobal TB Programme, WHO, Geneva, Switzerland.
Anna VassallDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.
Harvard Global Health Institute · USUniversity of London · GBWorld Health Organization · CHLondon School of Hygiene & Tropical Medicine · GBAmsterdam Institute for Global Health and Development · NLPublic Health Foundation of India · INUniversity of Cape Town · ZAYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Medical Research Council MR/P002404/1NCATS NIH HHS UL1 TR001863World Health Organization 001
6 · The paper itself

Abstract

backgroundThe economic burden on households affected by tuberculosis through costs to patients can be catastrophic. WHO's End TB Strategy recognises and aims to eliminate these potentially devastating economic effects. We assessed whether aggressive expansion of tuberculosis services might reduce catastrophic costs.

methodsWe estimated the reduction in tuberculosis-related catastrophic costs with an aggressive expansion of tuberculosis services in India and South Africa from 2016 to 2035, in line with the End TB Strategy. Using modelled incidence and mortality for tuberculosis and patient-incurred cost estimates, we investigated three intervention scenarios: improved treatment of drug-sensitive tuberculosis; improved treatment of multidrug-resistant tuberculosis; and expansion of access to tuberculosis care through intensified case finding (South Africa only). We defined tuberculosis-related catastrophic costs as the sum of direct medical, direct non-medical, and indirect costs to patients exceeding 20% of total annual household income. Intervention effects were quantified as changes in the number of households incurring catastrophic costs and were assessed by quintiles of household income.

findingsIn India and South Africa, improvements in treatment for drug-sensitive and multidrug-resistant tuberculosis could reduce the number of households incurring tuberculosis-related catastrophic costs by 6-19%. The benefits would be greatest for the poorest households. In South Africa, expanded access to care could decrease household tuberculosis-related catastrophic costs by 5-20%, but gains would be seen largely after 5-10 years.

interpretationAggressive expansion of tuberculosis services in India and South Africa could lessen, although not eliminate, the catastrophic financial burden on affected households.

fundingBill & Melinda Gates Foundation.

Indexed as

Health Care CostsCatastrophic IllnessHumansIndiaModels, TheoreticalSouth AfricaTuberculosis

Identifiers

PMID29025634
PMCPMC5640802
OpenAlexW2762446530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.